Advertisement

Kleinzellige Bronchialkarzinome

  • M. Wolf
  • K. Havemann

Zusammenfassung

Üblicherweise Anwendung findet die Klassifikation der WHO:
  • Haferzellkarzinom

  • Intermediärzellkarzinom

  • kombiniertes Haferzellkarzinom.

Ein Alternativvorschlag wurde von der IASLC (International Association for the Study of Lung Cancer) erarbeitet:
  • kleinzellig ohne Nachweis nichtkleinzelliger Anteile

  • kleinzellig mit großzelligen Anteilen

  • kleinzellig mit Adeno-und/oder Plattenepithelkarzinomanteilen.

Die einzelnen morphologischen Subtypen der WHO-Klassifikation weisen keine unterschiedliche Prognose auf. In der IASLC-Klassifikation soll die gemischt kleinzellig-großzellige Variante gegenüber der rein kleinzelligen mit einer ungünstigeren Prognose verbunden sein.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Livingston RB, Moore TN, Heilbrun L et al. (1978) Smallcell carcinoma of the lung combined chemotherapy and radiation. A Southwest Oncology Group Study. Ann Int Med 88: 194–199Google Scholar
  2. 2.
    Niederle N, Krischke W, Schulz U et al. (1982) Untersuchungen zur kurzzeitigen Induktions-und zyklischen Erhaltungstherapie beim inoperablen kleinzelligen Bronchialkarzinom. Kli Wo 60: 829–838CrossRefGoogle Scholar
  3. 3.
    Aisner J, Whitacre M, VanEcho DA et al. (1982) Doxorubicin, Cyclophosphamide and VP16–23 ( ACE) in the Treatment of Small Cell Lung Cancer. Cancer Chemother Pharmacol 7: 187–193Google Scholar
  4. 4.
    Wolf M, Drings P, Hans K et al. (1991) Alternating chemotherapy with Adriamycin/Ifosfamide/Vincristin (AO) and either Cisplatin/Etoposide (PE) or Carboplatin/Etoposide (JE) in small cell lung cancer (SCLC). Lunc Cancer 7 (Suppl), abs 527: 141Google Scholar
  5. 5.
    Drings P, Bülzebruck H, Hruska D et al. (1986) EPICO für die Behandlung des kleinzelligen Bronchialkarzinoms. 3. Zwischenanalyse. Onkologie 9 (Suppl 1): 14–20CrossRefGoogle Scholar
  6. 6.
    Jett JR, Everson L, Thernau TM et al. (1990) Treatment of limited stage small-cell lung cancer with Cyclophosphamide, Doxorubicin and Vincristine with or without Etoposide: A Randomized et Trail of the North Central Cancer Treatment Group. J Clin Oncol 8: 33–38Google Scholar
  7. 7.
    Wolf M, Havemann K, Holle R et al. (1987) Cisplatin-Etoposide versus Ifosfamide/Etoposide combination chemotherapy in small cell lung cancer: A Multicenter German Randomized Trial. J Clin Oncol 5: 1880–1889Google Scholar
  8. 8.
    Wilke H, Achterrath W, Schmoll H-J et al. (1988) Etoposide and splitt-dose Cisplatin in small-cell lung cancer. Am J Clin Oncol 11 (5): 572–578PubMedCrossRefGoogle Scholar
  9. 9.
    Jett JR, Su JQ, Maksymiuj AW et al. (1991) Phase III studies in the therapy of small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) Trial. Lung Cancer 7 (Suppl), abs 387: 106Google Scholar
  10. 10.
    Gatzemeier U, Hossfeld DK, Neuhaus R et al. (1992) Combinatin chemotherapy with Carboplatin, Etoposide and Vincristine as first-line treatment in small-cell lung cancer. J Clin Oncol 10: 818–823Google Scholar
  11. 11.
    Thatcher N, Lind M, Stout R et al. (1989) Carboplatin Ifosfamid and Etoposide with unid course vincristine and thoracic radiotherapy for limited stage small cell carcinoma of the bronchus. Br J Cancer 60: 98–101PubMedCrossRefGoogle Scholar
  12. 12.
    Wolf M, Pritsch M, Drings P et al. (1991) Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: A German Multicenter Randomized Trial of 321 patients. J Clin Oncol 9: 614–624PubMedGoogle Scholar
  13. 13.
    Giaccone G, Dalesio O, McVie GJ et al. (1993) Maintenance Chemotherapy in Small-Cell Lung Cancer: Long-Term Results of a Randomized Trial. J Clin Oncology 11: 1230–1240Google Scholar
  14. 14.
    Bleehen NM, Fayers PM, Girling DJ et al. (1989) Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer 59: 584–590CrossRefGoogle Scholar
  15. 15.
    Wolf M, Havemann K (1990) Alternierende Chemotherapie beim kleinzelligen Bronchialkarzinom. Onkologie 13: 157–164PubMedCrossRefGoogle Scholar
  16. 16.
    Evans WE, Feld R, Murray N et al. (1987) Superiority of alternating non-crossresistant chemotherapy in extensive small cell lung cancer. Ann of Int Med 107: 451–458CrossRefGoogle Scholar
  17. 17.
    Feld R, Evans WK, Coy P et al. (1987) Canadien Multicenter Randomized Trial Comparing Sequential and Alternating Administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 5: 1401–1409PubMedGoogle Scholar
  18. 18.
    Johnson DH, Arriagada R, Ihde DC et al. (1992) Meta analysis of Randomized Trials Evaluating the Role of Thoracic Radiotherapy (TRT) in Limited-Stage (LD) Small Cell Lung Cancer ( SCLC ). Proceedings of ASCO 11: 288Google Scholar
  19. 19.
    Turrisi AT, Wagner H, Glover D et al. (1990) Limited small cell lung cancer (LSCLC): Concurrent bid thoracic radiotherapy (TRT) with Platinum/Etoposide (PE): An ECOG Study. Proceedings of ASCO 9, abs 887Google Scholar
  20. 20.
    Johnson DH, Turrisis AT, Chang AY et al. (1993) Alternating Chemotherapy and Twice-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Pilot Study of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 11: 879–884Google Scholar
  21. 21.
    McCracken JD, Janaki LM, Crowley JJ et al. (1990) Concurrent Chemotherapy/ Radiochemotherapy for Limited Small-Cell Lung Carcinoma: A Southwest Oncology Group Study. Journal of Clinical Oncology 8: 892–898Google Scholar
  22. 22.
    Johnson DH, Kim K, Turrisi AT et al. (1994) Cisplatin (P)/Etoposide (E) + concurrent Thoracic Radiotherapy (TRT) adiministred once versus twice daily for limited stage (LS) small cell lung cancer (SCLC). Preliminary results of an intergroup trial Proc ASCO 13, p33, abs 1105Google Scholar
  23. 23.
    Murray N, Coy P, Pater JL et al. (1993) Importance of Timing for Thoracic Irradiation in the Combined Modality Treatment of Limited-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology 11: 336–344PubMedGoogle Scholar
  24. 24.
    Nielson OS, Fock K, Bentzen Set al. (1991) Timing of Radiotherapy and Chemotherapy in limited stage Small Cell Lung Cancer (LSCLC). Final Analysis EJC, Suppl 2, p 182, abs 1110Google Scholar
  25. 25.
    Arringada R, LeChevalier T, Borie F et al. (1994) Randomized trial on prophylactic cranial irradiation (PCI) for patients with small lung cancer in complete remission. Proc ASCO B, p 334, abs 1108Google Scholar
  26. 26.
    Ulsperger E, Karrer K, Denck H et al. (1991) Multimodality treatment for small cell bronchial carcinoma. European Journal of Cardiothoracic Surgery 5: 306–310PubMedCrossRefGoogle Scholar
  27. 27.
    Schirren J, Krysa S, Bülzebruck H et al. (1991) Das kleinzellige Bronchialkarzinom — eine Operationsindikation? Z Herz-, Thorax-, Gefäßchir 5: 260–266Google Scholar
  28. 28.
    Lad T, Thomas P, Piantadosi S et al. (1991) Surgical Resection of small-cell lung cancer — A prospective randomized Evaluation. Lung Cancer 7 (Suppl): abs 604Google Scholar
  29. 29.
    Shepherd FA, Ginsberg RJ, Feld R et al. (1991) Surgical treatment for limited small-cell lung cancer. J Thorac Cardiovasc Surg 101: 385–395PubMedGoogle Scholar
  30. 30.
    Miller PW, Earl HM, Sonhami RC et al. (1991) Intensive Weekly Chemotherapy for gott Prognosis Patients with Small Cell Lung Cancer. J Clin Oncol 9: 280-285Google Scholar
  31. 31.
    Miller DW, Spiro SG, Rudd RM et al. (1991) Interim Analysis of a randomized trial comparing 3 weekly versus weekly Chemotherapy in patients with small cell lung cancer. Lung Cancer 7 (Suppl), p 128, abs 476Google Scholar
  32. 32.
    Crawford J, Ozer H, Stoller R et al. (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Eng J Med 325: 164–170CrossRefGoogle Scholar
  33. 33.
    Hamm JT, Schiller J, Oken MM et al. (1993) ?? Ranging study of recombinant Human Granulocyte-Macrophage Colony stimulating Faktor in small cell lung cancer. Proc ASCO 12, p 335, abs 1118Google Scholar
  34. 34.
    Havemann K, Klausmann M, Wolf Met al. (1991) Effekt of rhGM-CSF on hematopoietic reconstitution afer chemotherapy in small cell lung cancer. J Cancer Res Clin Oncol 117 (Suppl IV): 203–207CrossRefGoogle Scholar
  35. 35.
    Spitzer G, Farha P, Valdivieso M et al. (1986) High-Dose Intensification Therapy with Autologous Bone Marrow Support for Limited Small-Cell Bronchogenic Carcinoma. J Clin Oncology 4: 4–13Google Scholar
  36. 36.
    Elias AD, Ayash L, Wheeler C et al. (1992) High Dose Combinaton Alkylating Agents Supported by Autologous Marrow (ABMT) with Chest Radiotherapy for Responding Limited Stage (LD) Small Cell Lung Cancer. Proceedings of ASCO 11: abs 991Google Scholar
  37. 37.
    Bork E, Sigsgaard T, Nissen KM et al. (1991) Etoposide and Temiposide in untreated small cell lung cancer. Lung Cancer 7 (Suppl), p 121, abs 449Google Scholar
  38. 38.
    Morgan D, Gilson D, Fletcher J (1987) Vincristine and Etoposide. An effective chemotherapy regimen with reduced toxicity in extensive small cell lung cancer. Eur J Cancer Clin Oncol 23: 619–621Google Scholar
  39. 39.
    Sculier JP, Klastersky J, Libert P et al. (1990) A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. Annals of Oncology 1: 128–133PubMedGoogle Scholar
  40. 40.
    Gatzmeier U, Heckmayr M, Neuhauss R et al. (1994) Chemotherapy of extensive small cell lung cancer — a randomized trial with carboplatin/etoposide/vincristine vs. etoposide/vincristine alone. J Cancer Res Clin Oncol 120 (Suppl) R24, 05.05. 05Google Scholar
  41. 41.
    Wolf M, Pritsch M, Drings P et al. (1994) Standard vs. palliative Chemotherapy in metastatic small cell lung cancer. An analysis of treatment efficacy and quality of life. Lung Cancer 1 (Suppl 1), p 92, abs 349Google Scholar
  42. 42.
    Hainsworth JD, Johnson D, Frazier SR, Greco A (1989) Chronic daily administration of oral Etoposide. A Phase I Trial J Clin Oncol 7: 396–401Google Scholar
  43. 43.
    Miller AA, Herudon J, Hollis D et al. (1994) Phase III Study of 21 day arol versus 3 day i.v. Etoposide in combination with Cisplatin in extensive small cell lung cancer. A CACGB Study. Proc aSCO 13, p326, abs 1974Google Scholar
  44. 44.
    Earl HM, Rudd RM, Spiro SG et al. (1991) A randomised trial of planned versus required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 64: 566–572PubMedCrossRefGoogle Scholar
  45. 45.
    Murray N, Shad A, Osoba D et al. (1991) Intensive weekly chemotherapy for the Treatment of Extensive stage small cell lung cancer. J Clin Oncol 9: 1632–1638PubMedGoogle Scholar
  46. 46.
    Mattson U, Niiranen A, Pyrhönen Set al. (1992) Natural Interferon Alfa as maintenance therapy for Small Cell Lung Cancer. Eur J Cancer 28: 1387–1391CrossRefGoogle Scholar
  47. 47.
    Kelly K, Bunn PA, Hazuka M et al. (1993) The role of alpha Interferon maintenance therapy in patients with limited stage SCLC responding to concurrent chemoradiotherapy. Proc ASCO p 320, abs 1092Google Scholar
  48. 48.
    Lebeau B, Chastang Ce et al. (1991) Subcutaneous heparin treatment increases complete response rate and overall survival in small cell lung cancer (SCLC). Lung Cancer 7 (Suppl), abs 480: 129Google Scholar
  49. 49.
    Maurer LH, Herudon JE, Hollis DR et al. (1993) A randomized trial for chemotherapy and radiation with or without werfarin for limited disease small cell lung cancer. Proc ASCO 12, p 335, abs 1119Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • M. Wolf
  • K. Havemann

There are no affiliations available

Personalised recommendations